This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2050 Remove DEA Remove Patients Related Topics
Medical Evaluation State Laws Collective Epilepsy Access Data Compliance Extraction Safety Legalization More Related Topics >
article thumbnail

Constitutionality of Cannabis: Federal Lawsuit Against DEA, DOJ Proceeds

Marijuana Lawyer Blog

JANUARY 12, 2019

As our Los Angeles marijuana patient attorneys can explain, the crux of the argument by plaintiffs of the claim, first filed in 2017, is that the designation ignores the merits of the drug for medicinal purposes. Defendants are acting-Attorney General Matthew Whitaker, the acting director of the DEA and the federal government.

DEA 40
DEA Patients Epilepsy Medicine 40
article thumbnail

Further Consideration of the STATES Act

Cannabis Law Report

MARCH 25, 2019

The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. 2050 , 2051, 2075; Pub. 2050 , 2051, 2075; Pub. 301(a), Nov. 10, 1978 , 92 Stat. 3777 ; Pub.

Banking 45
Banking Law Marijuana State Laws 45
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 24,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024